retatrutide glp-1 gip glucagon receptor agonist How Does Work? Doctor Explains Why It's So Effective Structural insights into the triple

however, most phase III clinical studies are of insufficient duration and do not include enough study participants to effectively gauge long-term safety

Weight loss on GLP-1 RAs is accompanied by improvements in cardiometabolic markers (glycemia, lipids, blood pressure) and has spurred investigation of GLP-1 RA therapy for obesity itself, independent of diabetes

PubMed, Gupta, Dharmendra Kumar, and Arunima Chaudhuri

placebo at 6 months] 1.3, 95%CI 0.891.88) in 300 people with HF, with and without type 2 diabetes and with recent decompensation (Margulies et al., 2016)

In a recently published phase II study conducted on 92 T2D patients with a BMI 27 kg/m 2 , a 2.18% decrease in HbA1c and a 15.6% reduction in body weight were confirmed in the group administered CagriSema once a week [102]